JAK2 and non-small cell lung carcinoma: This is observed in NSCLC, where long-term treatment with gefitinib suppresses EGFR/STAT3 signaling, but results in a compensatory increase in SRC/STAT3 and JAK2/STAT3 pathways that upregulate STAT3 activation [264].